We are live on ! Find out more
OCEA

Ocean Biomedical, Inc. Common Stock
OCEA

Delisted

OCEA was delisted on the 23rd of April, 2025.

Back to rankings

40 hedge funds and large institutions have $106M invested in Ocean Biomedical, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 1 increasing their positions, 6 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

167% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 3

14% more funds holding

Funds holding: 35 → 40 (+5)

3% more capital invested

Capital invested by funds: $103M → $106M (+$3M)

83% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 6

Holders
40
Holders Change
+5
Holders Change %
+14.29%
% of All Funds
0.69%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
1
Reduced
6
Closed
3
Calls
$143K
Puts
–
Net Calls
+$143K
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PAMP
Polar Asset Management Partners
Ontario, Canada
+$8.41M
2
WP
Woodline Partners
California
+$2.29M
3
MC
Meteora Capital
Florida
+$1.41M
4
Calamos Advisors
Calamos Advisors
Illinois
+$1.27M
5
WA
Whitebox Advisors
Minnesota
+$1.05M

Top Sellers

Rank Fund Capital Flow
1
MSU
Mizuho Securities USA
New York
-$6.68M
2
WAM
Wolverine Asset Management
Illinois
-$4.68M
3
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$734K
4
PCM
Pinz Capital Management
New York
-$607K
5
Goldman Sachs
Goldman Sachs
New York
-$364K
Name Holding Trade Value Shares
Change 		Change in
Stake
PAMP
1
Polar Asset Management Partners
Ontario, Canada
$8.41M +$8.41M +825,000 New
SCM
2
Shaolin Capital Management
Florida
$8.12M – – –
SCM
3
Saba Capital Management
New York
$7.48M – – –
BFM
4
Boothbay Fund Management
New York
$6.13M +$12.4K +1,219 +0.2%
ASM
5
ATW SPAC Management
New York
$6.11M – – –
WAM
6
Weiss Asset Management
Massachusetts
$6.11M -$5.41K -531 -0.1%
FTCM
7
First Trust Capital Management
Illinois
$5.79M – – –
Hudson Bay Capital Management
8
Hudson Bay Capital Management
Connecticut
$5.38M -$734K -72,000 -12%
D.E. Shaw & Co
9
D.E. Shaw & Co
New York
$5.35M – – –
CCM
10
Context Capital Management
California
$5.07M – – –
PC
11
Periscope Capital
Ontario, Canada
$4.32M – – –
MI
12
MMCAP International
Cayman Islands
$4.08M – – –
YCM
13
Yakira Capital Management
Connecticut
$4.08M – – –
WRBC
14
W.R. Berkley Corp
Connecticut
$3.75M – – –
Marshall Wace
15
Marshall Wace
United Kingdom
$2.83M – – –
CH
16
CVI Holdings
Delaware
$2.62M – – –
KIM
17
Karpus Investment Management
New York
$2.52M -$111K -10,900 -4%
WP
18
Woodline Partners
California
$2.29M +$2.29M +225,000 New
6CM
19
683 Capital Management
New York
$1.53M – – –
SV
20
Starboard Value
New York
$1.47M – – –
MC
21
Meteora Capital
Florida
$1.41M +$1.41M +138,757 New
KL
22
KIM LLC
Kansas
$1.38M – – –
Calamos Advisors
23
Calamos Advisors
Illinois
$1.27M +$1.27M +125,000 New
WA
24
Whitebox Advisors
Minnesota
$1.05M +$1.05M +102,800 New
Millennium Management
25
Millennium Management
New York
$1.02M -$11.4K -1,120 -1%
1
2

OCEA Hedge Fund Activity: Q3 2022 in Review

40 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Ocean Biomedical, Inc. Common Stock (OCEA) for Q3 2022, worth a combined $106M — up 2.9% from $103M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new OCEA positions and 3 closed out — a net gain of 5 holders — while 1 added to existing stakes and 6 trimmed.

The largest buyer was Polar Asset Management Partners, opening a new position worth an estimated $8.41M. The largest seller was Mizuho Securities USA, exiting entirely with an estimated $6.68M sold.

  • 40 institutional investors held Ocean Biomedical, Inc. Common Stock (OCEA) as of Q3 2022, up from 35 in Q2 2022.
  • Funds reported $106M of Ocean Biomedical, Inc. Common Stock stock for Q3 2022, up 2.9% quarter-over-quarter.
  • 8 funds opened new Ocean Biomedical, Inc. Common Stock positions in Q3 2022 and 3 closed out, a net change of +5 holders.
  • The largest Ocean Biomedical, Inc. Common Stock buyer in Q3 2022 was Polar Asset Management Partners, an estimated $8.41M added.
  • The largest Ocean Biomedical, Inc. Common Stock seller in Q3 2022 was Mizuho Securities USA, an estimated $6.68M sold.

Based on aggregated 13F filings for Q3 2022.